There were 907 press releases posted in the last 24 hours and 358,267 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
OSE Immunotherapeutics Signs a License Option Agreement with Inserm to Develop a New Cancer Immunotherapy Targeting Myeloid Cells

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image